Endevica Bio News
Endevica Bio Raises $10 Million in Series B Financing to Advance Development of TCMCB07 for Treatment of Cachexia
We have never been more encouraged about the future of our company and the research it is doing to treat those suffering from cachexia. Our recently closed $10 million Series B funding will help us advance the clinical development of TCMB07, achieve additional milestones and help the millions of people with cachexia. Read more in our press release: https://bwnews.pr/3GSgchd
Kenneth Gruber, CSO, along with his colleagues published important data surrounding our lead therapeutic, TCMCB07, in the journal ACS Pharmacology & Translational Science.
The research describes the unique mechanisms and properties of the drug, specifically in the treatment of cachexia, information and a link to the research: https://lnkd.in/ghAQDGBF
PharmaVoice article "From angel to operator: The unlikely journey of Endevica Bio's CEO"
To learn more about our #cachexia drug in development and CEO Russell Potterfield: https://bit.ly/3I7lFQ
Endevica Bio Appoints Prominent Cachexia Physician, Daniel Marks MD, PhD, as Chief Medical Officer
Endevica Bio Featured as a Life Science Leader "Company to Watch"
Discussing Endevica’s lead drug for caxechia and CEO Russell Potterfield’s vision for Endevica
CEO Russell Potterfield discusses the benefits of Endevica's lead compound for cachexia with BioSpace
CEO Russell Potterfield interviewed by Pharma Scrip
CEO Russell Potterfield speaks about venture capital and biopharma
Founder Kenneth Gruber featured on the Your Family's Health Podcast
Endevica Founder Kenneth Gruber interviewed in The Medicine Maker
Best Startup names Endevica Bio one of the best therapeutic companies in Missouri
Endevica Bio Featured in Cancer Wellness Magazine
Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study
Researcher Dr. Zhu at the Marks lab concludes that TCMCB07 is a promising drug candidate with universal effects on treating cancer cachexia.
Behind the scenes at Endevica Bio
Russell Potterfield shares his journey as an entrepreneur and the Executive chairman of Endevica Bio
Changing focus to cachexia may be the key to improved cancer outcomes
Researcher Dr. Dan Marks explains the relationship between cancer outcomes and cachexia
Endevica Bio Begins IND-Enabling Toxicology Studies
IND enabling toxicology studies for Endevica Bio’s cancer cachexia therapeutic are underway with an IND anticipated January of 2022.
Tensive Controls, Inc. Announces new name, Endevica Bio
Executive Chairman, Russell Potterfield announces that this will be the first of many milestones the company will achieve this year.
Article published in Drug Discovery & Development
Investigational drug promises to reverse wasting syndrome in cancer patients.
Marks joins the Board of Directors
Dr. Dan Marks, longtime researcher in the field of Cachexia, joins the Board of Directors.
New publication in JCI
New publication in JCSM
New Executive Chairman
Russell Potterfield is named Executive Chairman of the Board of Directors of Tensive Controls, Inc.
Transition to Phase 2 of NIH Grant
TCI Peptide’s demonstrated progress toward development path milestones and successfully transitioned to Phase 2 of the National Cancer Institute Grant.
Nationwide Clinical Trial Opened
Clinical trial sites from major veterinary hospital groups were opened to augment recruitment efforts at the University of Missouri School of Veterinary Medicine.
NIH Grant Awarded
TCI Peptide’s was awarded a $2.3 million grant from the National Cancer Institute to further advance research and development of a melanocortin-based therapeutic for cancer cachexia.
Patent Issued
The USPTO issued a Notice of Allowance for a patent application protecting the company’s technology platform.
Patent Issued
The EPO granted a European Patent for the company’s application dealing with suppression of cardiovascular side effects in melanocortin analogs intended for therapeutic and related uses.
Series A Completed
TCI Peptide’s completed a $1.7 million financing round through Centennial Investors Angel Investor Network. Funds will be used to advance the development of applications of the company’s technology platform for modifying peptides with applications in human and animal health.